Literature DB >> 31436584

Biomarkers in systemic sclerosis.

Brian Skaug1, Shervin Assassi.   

Abstract

PURPOSE OF REVIEW: To discuss recent advances in identification of biomarkers in systemic sclerosis for disease severity, prognosis, and treatment response. RECENT
FINDINGS: Recent reports describe novel circulating markers of disease severity, autoantibody associations with specific manifestations including cancer, and skin gene expression-based predictors of modified Rodnan skin score progression and treatment response. Moreover, there is converging evidence that C-reactive protein and pneumoproteins such as Krebs von den Lungen-6 and chemokine ligand 18 could serve as prognostic biomarkers in systemic sclerosis-associated interstitial lung disease.
SUMMARY: Several novel biomarkers show promise in improving the assessment of systemic sclerosis (SSc) disease severity, prognosis, and treatment response. Their potential utility in prospective selection of patients for clinical trials and in individual patient management require additional research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31436584      PMCID: PMC7185900          DOI: 10.1097/BOR.0000000000000656

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  48 in total

1.  Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.

Authors:  Katie Streicher; Sriram Sridhar; Mike Kuziora; Christopher A Morehouse; Brandon W Higgs; Yinong Sebastian; Christopher J Groves; Fernanda Pilataxi; Philip Z Brohawn; Ronald Herbst; Koustubh Ranade
Journal:  Arthritis Rheumatol       Date:  2018-10-22       Impact factor: 10.995

2.  Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

Authors:  Britta Maurer; Nicole Graf; Beat A Michel; Ulf Müller-Ladner; László Czirják; Christopher P Denton; Alan Tyndall; Carola Metzig; Vivian Lanius; Dinesh Khanna; Oliver Distler
Journal:  Ann Rheum Dis       Date:  2014-06-30       Impact factor: 19.103

3.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Authors:  Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2010-08-02       Impact factor: 19.103

4.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

6.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

Review 7.  An update on autoantibodies in scleroderma.

Authors:  Christopher A Mecoli; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2018-11       Impact factor: 5.006

Review 8.  Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement.

Authors:  Robyn T Domsic
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

9.  A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets.

Authors:  Jennifer M Franks; Viktor Martyanov; Guoshuai Cai; Yue Wang; Zhenghui Li; Tammara A Wood; Michael L Whitfield
Journal:  Arthritis Rheumatol       Date:  2019-09-02       Impact factor: 15.483

10.  Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.

Authors:  Jayne Moxey; Molla Huq; Susanna Proudman; Joanne Sahhar; Gene-Siew Ngian; Jenny Walker; Gemma Strickland; Michelle Wilson; Laura Ross; Gabor Major; Janet Roddy; Wendy Stevens; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2019-02-14       Impact factor: 5.156

View more
  8 in total

1.  Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model.

Authors:  Kai Li; Qian Wang; Qin Lv; Kelei Guo; Li Han; Peipei Duan; Yongzheng Deng; Hua Bian
Journal:  BMC Complement Med Ther       Date:  2022-06-22

Review 2.  Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.

Authors:  Anna Kowalska-Kępczyńska
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

Review 3.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

4.  Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins.

Authors:  Edward P Stern; Robert Unwin; Aine Burns; Voon H Ong; Christopher P Denton
Journal:  Rheumatol Adv Pract       Date:  2021-01-07

5.  18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study.

Authors:  Emmanuel Ledoult; Maxime Morelle; Clio Baillet; David Launay; Michael Soussan; Arsène Mékinian; Hélène Béhal; Vincent Sobanski; Eric Hachulla; Damien Huglo; Noémie Le Gouellec; Martine Remy-Jardin
Journal:  Arthritis Res Ther       Date:  2021-03-06       Impact factor: 5.156

6.  Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?

Authors:  Victor Farutin; Elma Kurtagic; Joël R Pradines; Ishan Capila; Maureen D Mayes; Minghua Wu; Anthony M Manning; Shervin Assassi
Journal:  Arthritis Res Ther       Date:  2021-10-15       Impact factor: 5.156

7.  Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis.

Authors:  Liticia Chikhoune; Thierry Brousseau; Sandrine Morell-Dubois; Meryem Maud Farhat; Helene Maillard; Emmanuel Ledoult; Marc Lambert; Cecile Yelnik; Sebastien Sanges; Vincent Sobanski; Eric Hachulla; David Launay
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

8.  Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis.

Authors:  Jozsef A Balog; Agnes Kemeny; Laszlo G Puskas; Szilard Burcsar; Attila Balog; Gabor J Szebeni
Journal:  Mediators Inflamm       Date:  2021-06-17       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.